Summary
No AI-generated prescribing/label claims were provided to evaluate against the supplied XELODA (capecitabine) FDA labeling excerpts; alignment cannot be assessed.
Category Scores
Accurate Statements
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No specific AI statements were evaluated; therefore no medication guidance was confirmed or refuted. Risk is assessed as low due to absence of actionable claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Assessable
Primary Issue
Missing AI-generated response content/claims to compare against the provided FDA label excerpts.
Suggested Improvement
Provide the exact AI-generated text (verbatim) containing the prescribing/label claims to be audited, then the audit can be performed against the relevant XELODA label sections (e.g., 5.1 DPD deficiency/fatal toxicity, 5.2–7.2 warfarin/vitamin K antagonist bleeding/death, 5.3 cardiotoxicity, 5.4 diarrhea, and 2.1 DPD testing).